Tag Archives: AMRN

Healthcare Sector Overview: Pfizer (NYSE:PFE), Aetna (NYSE:AET) – PFE, AET, JNJ, AMRN, DCTH, ZIOP

Posted on May 1, 2013 by Thomas Vedder

Tuesday’s trading session data confirmed that healthcare sector reacted negatively with -0.91% change. Amarin Corporation plc (ADR) (NASDAQ:AMRN) was major percentage gainer in this sector while key percentage decliners were Delcath Systems, Inc (NASDAQ:DCTH) and ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Pfizer …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Amarin, AMRN, DCTH, Delcath, JNJ, Johnson, NASDAQ:AMRN, NASDAQ:DCTH, NASDAQ:ZIOP, NYSE:AET, NYSE:JNJ, NYSE:PFE, PFE, Pfizer, ZIOP, ZIOPHARM Oncology | Comments Off

Healthcare Sector Roundup: Cardium Therapeutics (NYSE:CXM), Rigel Pharmaceuticals (NASDAQ:RIGL) – CXM, RIGL, AZN, RIGL, AMRN, PFE

Posted on April 6, 2013 by Thomas Vedder

Healthcare sector finished in red land on Friday trading session and sector plunged -0.58%. If we consider key percentage decliners so Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) and Amarin Corporation plc (ADR) (NASDAQ:AMRN) were key stocks while most active stock was Pfizer …

Posted in Healthcare, Latest Headlines | Tagged Amarin, AMRN, AstraZeneca, AZN, Cardium Therapeutics, CXM, NASDAQ:AMRN, NASDAQ:RIGL, NYSE:AZN, NYSE:CXM, NYSE:PFE, PFE, Pfizer, Rigel Pharmaceuticals, RIGL | Comments Off

FTC New Topic of Scrutiny; Herbalife (NYSE:HLF) – DNDN, AMRN, ABBV, TEVA, BMY, CLS, HLF, BIDU, SBUX

Posted on February 4, 2013 by Thomas Vedder

On Monday, Herbalife (NYSE:HLF) the nutritional products distributor, is under investigation by the Federal Trade Commission, as per reported to the New York Post.

The report mentioned that the FTC has got 192 complaints against the company in the past …

Posted in Healthcare, Latest Headlines | Tagged ABBV, AbbVie, Amarin Corporation, AMRN, Baidu, BIDU, BMY, Bristol-Myers Squibb, Celsion, CLS, Dendreon, DNDN, Herbalife, HLF, NASDAQ:AMRN, NASDAQ:BIDU, NASDAQ:CLS, NASDAQ:DNDN, NASDAQ:SBUX, NYSE:ABBV, NYSE:BMY, NYSE:HLF, NYSE:TEVA, SBUX, Starbucks, TEVA, Teva Pharmaceutical Industries | Comments Off

Healthcare Sector Gets Boost; Pfizer (PFE) Plans to Add $2.2 Billion from Zoetis IPO while UnitedHealth (UNH) Fiscal Q4 Net Tumbles – PFE, UNH, JNJ, AMRN, SGMO, THRX

Posted on January 18, 2013 by Geoff Noir

Healthcare sector reacted positively on Thursday with the whole market and sector hiked +0.74%. If we look at the top movers of the sector so Amarin Corporation plc (ADR) (NASDAQ:AMRN) and Sangamo Biosciences, Inc (NASDAQ:SGMO) were major percentage gainers while …

Posted in Healthcare, Latest Headlines | Tagged Amarin, AMRN, JNJ, Johnson, NASDAQ:AMRN, NASDAQ:SGMO, NASDAQ:THRX, NYSE:JNJ, NYSE:PFE, NYSE:UNH, PFE, Pfizer, Sangamo Biosciences, SGMO, Theravance, THRX, UNH, UnitedHealth | Comments Off

Pernix Therapeutics (NYSE:PTX) To Acquire Somaxon (SOMX); $25 Million Accord – PTX, CRME, DEPO, AGN, DVAX, AMRN, ALXA, PFE, JNJ

Posted on December 11, 2012 by Thomas Vedder

Pernix Therapeutics Holdings Inc (NYSE:PTX) reported on Tuesday that it is purchasing Somaxon Pharmaceuticals, Inc (NASDAQ:SOMX) in a stock-for-stock agreement, worth at $25 million.

The Woodlands, Texas based Pernix anticipates to benefit from Somaxon’s insomnia drug Silenor in the purchase, …

Posted in Healthcare, Latest Headlines | Tagged AGN, Alexza Pharmaceuticals, Allergan, ALXA, Amarin, AMRN, CARDIOME PHARMA, CRME, DEPO, Depomed, DVAX, Dynavax Technologies, JNJ, Johnson & Johnson, NASDAQ:ALXA, NASDAQ:AMRN, NASDAQ:CRME, NASDAQ:DEPO, NASDAQ:DVAX, NYSE:AGN, NYSE:JNJ, NYSE:PFE, NYSEAMEX:PTX, Pernix Therapeutics, PFE, Pfizer, PTX | Comments Off

Magellan Health (NASDAQ:MGLN) Provides Weak Outlook for Fiscal 2013; Picks Barry Smith as CEO – MGLN, ACUR, JNJ, GSK, AMRN, HCA, BSX

Posted on December 11, 2012 by Thomas Vedder

Magellan Health Services Inc (NASDAQ:MGLN) offered its 2013 estimates, by anticipating net revenue between $3.56 billion to $3.74 billion, net income in the range of $91 million to $109 million, translating into EPS of $3.22 to $3.85 inclusive of share …

Posted in Healthcare, Latest Headlines | Tagged ACUR, Acura Pharmaceuticals, Amari, AMRN, Boston Scientific, BSX, GlaxoSmithKline, GSK, HCA, HCA Holdings, JNJ, Johnson & Johnson, Magellan Health, MGLN, NASDAQ:ACUR, NASDAQ:MGLN, NYSE:BSX, NYSE:GSK, NYSE:HCA, NYSE:JNJ | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.